Literature DB >> 17416342

The liver X receptor agonist T0901317 acts as androgen receptor antagonist in human prostate cancer cells.

Chih-Pin Chuu1, Rou-Yu Chen, Richard A Hiipakka, John M Kokontis, Karen V Warner, Jialing Xiang, Shutsung Liao.   

Abstract

T0901317 is a potent non-steroidal synthetic liver X receptor (LXR) agonist. T0901317 blocked androgenic stimulation of the proliferation of androgen-dependent LNCaP 104-S cells and androgenic suppression of the proliferation of androgen-independent LNCaP 104-R2 cells, inhibited the transcriptional activation of an androgen-dependent reporter gene by androgen, and suppressed gene and protein expression of prostate specific antigen (PSA), a target gene of androgen receptor (AR) without affecting gene and protein expression of AR. T0901317 also inhibited binding of a radiolabeled androgen to AR, but inhibition was much weaker compared to the effect of the antiandrogens, bicalutamide and hydroxyflutamide. The LXR agonist T0901317, therefore, acts as an antiandrogen in human prostate cancer cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17416342      PMCID: PMC2693411          DOI: 10.1016/j.bbrc.2007.03.116

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  37 in total

1.  Identification of a nonsteroidal liver X receptor agonist through parallel array synthesis of tertiary amines.

Authors:  Jon L Collins; Adam M Fivush; Michael A Watson; Cristin M Galardi; Michael C Lewis; Linda B Moore; Derek J Parks; Joan G Wilson; Tim K Tippin; Jane G Binz; Kelli D Plunket; Daniel G Morgan; Elizabeth J Beaudet; Karl D Whitney; Steven A Kliewer; Timothy M Willson
Journal:  J Med Chem       Date:  2002-05-09       Impact factor: 7.446

Review 2.  The current state of hormonal therapy for prostate cancer.

Authors:  Beth A Hellerstedt; Kenneth J Pienta
Journal:  CA Cancer J Clin       Date:  2002 May-Jun       Impact factor: 508.702

3.  Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer.

Authors:  M J Linja; K J Savinainen; O R Saramäki; T L Tammela; R L Vessella; T Visakorpi
Journal:  Cancer Res       Date:  2001-05-01       Impact factor: 12.701

4.  A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens.

Authors:  J Veldscholte; C Ris-Stalpers; G G Kuiper; G Jenster; C Berrevoets; E Claassen; H C van Rooij; J Trapman; A O Brinkmann; E Mulder
Journal:  Biochem Biophys Res Commun       Date:  1990-12-14       Impact factor: 3.575

5.  Calcium phosphate-mediated gene transfer: a highly efficient transfection system for stably transforming cells with plasmid DNA.

Authors:  C A Chen; H Okayama
Journal:  Biotechniques       Date:  1988 Jul-Aug       Impact factor: 1.993

6.  Real-time RT-PCR for the measurement of prostate-specific antigen mRNA expression in benign hyperplasia and adenocarcinoma of prostate.

Authors:  Stefania Gelmini; Carmela Tricarico; Luisa Petrone; Gianni Forti; Andrea Amorosi; Giovanni L Dedola; Mario Serio; Mario Pazzagli; Claudio Orlando
Journal:  Clin Chem Lab Med       Date:  2003-03       Impact factor: 3.694

7.  DNA fluorometric assay in 96-well tissue culture plates using Hoechst 33258 after cell lysis by freezing in distilled water.

Authors:  R Rago; J Mitchen; G Wilding
Journal:  Anal Biochem       Date:  1990-11-15       Impact factor: 3.365

8.  Androgen receptor gene amplification and protein expression in recurrent prostate cancer.

Authors:  O Harris Ford; Christopher W Gregory; Desok Kim; Andrew B Smitherman; James L Mohler
Journal:  J Urol       Date:  2003-11       Impact factor: 7.450

9.  Antidiabetic action of a liver x receptor agonist mediated by inhibition of hepatic gluconeogenesis.

Authors:  Guoqing Cao; Yu Liang; Carol L Broderick; Brian A Oldham; Thomas P Beyer; Robert J Schmidt; Youyan Zhang; Keith R Stayrook; Chen Suen; Keith A Otto; Anne R Miller; Jiannong Dai; Patricia Foxworthy; Hong Gao; Timothy P Ryan; Xian-Cheng Jiang; Thomas P Burris; Patrick I Eacho; Garret J Etgen
Journal:  J Biol Chem       Date:  2002-10-31       Impact factor: 5.157

10.  T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice.

Authors:  Naoki Terasaka; Ayano Hiroshima; Tadashi Koieyama; Naoko Ubukata; Yuka Morikawa; Daisuke Nakai; Toshimori Inaba
Journal:  FEBS Lett       Date:  2003-02-11       Impact factor: 4.124

View more
  20 in total

1.  Cross-talk between the androgen receptor and the liver X receptor: implications for cholesterol homeostasis.

Authors:  James Robert Krycer; Andrew John Brown
Journal:  J Biol Chem       Date:  2011-04-13       Impact factor: 5.157

Review 2.  Targeting liver X receptors in cancer therapeutics.

Authors:  Chin-Yo Lin; Jan-Åke Gustafsson
Journal:  Nat Rev Cancer       Date:  2015-03-19       Impact factor: 60.716

3.  Androgen suppresses proliferation of castration-resistant LNCaP 104-R2 prostate cancer cells through androgen receptor, Skp2, and c-Myc.

Authors:  Chih-Pin Chuu; John M Kokontis; Richard A Hiipakka; Junichi Fukuchi; Hui-Ping Lin; Ching-Yu Lin; Chieh Huo; Chiech Huo; Liang-Cheng Su; Shutsung Liao
Journal:  Cancer Sci       Date:  2011-08-18       Impact factor: 6.716

4.  Cytosolic sulfotransferase 2B1b promotes hepatocyte proliferation gene expression in vivo and in vitro.

Authors:  Xin Zhang; Qianming Bai; Leyuan Xu; Genta Kakiyama; William M Pandak; Zhigang Zhang; Shunlin Ren
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-06-07       Impact factor: 4.052

5.  Anti-proliferative effect of LXR agonist T0901317 in ovarian carcinoma cells.

Authors:  James J Rough; M Alexandra Monroy; Smitha Yerrum; John M Daly
Journal:  J Ovarian Res       Date:  2010-05-26       Impact factor: 4.234

6.  LXR, prostate cancer and cholesterol: the Good, the Bad and the Ugly.

Authors:  Hugues de Boussac; Aurélien Jc Pommier; Julie Dufour; Amalia Trousson; Françoise Caira; David H Volle; Silvère Baron; Jean-Marc A Lobaccaro
Journal:  Am J Cancer Res       Date:  2013-01-18       Impact factor: 6.166

7.  Suppression of androgen receptor signaling and prostate specific antigen expression by (-)-epigallocatechin-3-gallate in different progression stages of LNCaP prostate cancer cells.

Authors:  Chih-Pin Chuu; Rou-Yu Chen; John M Kokontis; Richard A Hiipakka; Shutsung Liao
Journal:  Cancer Lett       Date:  2008-11-01       Impact factor: 8.679

8.  Caffeic acid phenethyl ester suppresses the proliferation of human prostate cancer cells through inhibition of p70S6K and Akt signaling networks.

Authors:  Chih-Pin Chuu; Hui-Ping Lin; Mark F Ciaccio; John M Kokontis; Ronald J Hause; Richard A Hiipakka; Shutsung Liao; Richard Baker Jones
Journal:  Cancer Prev Res (Phila)       Date:  2012-05

9.  Negative regulation of Hedgehog signaling by liver X receptors.

Authors:  Woo-Kyun Kim; Vicente Meliton; Kye Won Park; Cynthia Hong; Peter Tontonoz; Pawel Niewiadomski; James A Waschek; Sotirios Tetradis; Farhad Parhami
Journal:  Mol Endocrinol       Date:  2009-07-16

10.  LXR activation causes G1/S arrest through inhibiting SKP2 expression in MIN6 pancreatic beta cells.

Authors:  Yating Li; Changwen Jing; Xinyi Tang; Yuanyuan Chen; Xiao Han; Yunxia Zhu
Journal:  Endocrine       Date:  2016-04-12       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.